We can't start a potentially approvable trial and stay at these levels.
We can't have a drug that's seemingly best on offer, with a combo study result out shortly (opening doors for co-lab discussions with major pharma players), to not move north.
And covid still does seem to hang around, whilst we've not yet got anything happening there that doesn't mean we wont, I doubt a new exec to our team would mention it in recent webinars if he thought it was redundant.
sit tight we can only go up.
ANP - Interesting general news items in BIO, page-92
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |